Skip to main content
padlock icon - secure page this page is secure

New Epigallocatechin Gallate (EGCG) Nanocomplexes Co-Assembled with 3-Mercapto-1-Hexanol and β-Lactoglobulin for Improvement of Antitumor Activity

Buy Article:

$106.34 + tax (Refund Policy)

(-)-Epigallocatechin-3-gallate (EGCG), as the major catechin in green tea, is a potent antioxidant with numerous reported health benefits such as anti-proliferative and pro-apoptotic effects. Nanovehicles for EGCG delivery can effectively improve its antioxidant capacity, absorbability and bioavailability in vivo. We used thermally modified β-lactoglobulin (β-Lg), 3-mercapto-1-hexanol (3MH) and EGCG to form stable co-assembled nanocomplexes (MEβ-NPs) with greater stability, sustained release and anticancer effects in vitro and in vivo than free EGCG. MEβ-NPs inhibited A375, Hep G2 and TE-1 tumor cell proliferation with 65.90%, 60.44% and 32.88% greater activity, respectively, than EGCG. MEβ-NPs with 100 mg EGCG/kg (3MH/EGCG/β-LG = 4:32:1) were not toxic to mice and inhibited implanted human melanoma A375 cell tumor growth by 57.78%, twice as effective as EGCG alone. Thus, MEβ-NPs have greater stability and antitumor activity than EGCG, with potential value for anticancer therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: July 1, 2017

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more